Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003339 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00003339 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 48 participants.
The verdict
NCT00003339, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to determine the effectiveness of vaccine therapy given with interleukin-12 in treating patients who have stage III or stage IV melanoma.
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL recombinant interleukin-12
- BIOLOGICAL gp100 antigen
- BIOLOGICAL tyrosinase peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1998-11 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003339
The ClinicalTrials.gov registry entry for NCT00003339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00003339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003339 about?
NCT00003339 is a clinical study titled "Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to det...
What is the current status of trial NCT00003339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 1998-11. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00003339?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), recombinant interleukin-12 (BIOLOGICAL), gp100 antigen (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003339?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.